Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone may leads to lower secondary malignant neoplasms compared with same chemotherapy plus radiotherapy (low certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone showed no clear difference in death compared with same chemotherapy plus radiotherapy (moderate certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone showed no clear difference in progression/relapse compared with same chemotherapy plus radiotherapy (moderate certainty).
1 finding from 1 review
Time to symptom resolution · outpatients withmild disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in time to symptom resolution (absolute effect calculated for day 12) compared with placebo or standard care alone (low certainty).
1 finding from 1 review
Infections (all grades) · people with chronic lymphocytic leukaemia
Anti‐leukaemic therapy plus alemtuzumab may leads to higher infections (all grades) compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (low certainty).
1 finding from 1 review
Severe adverse effects (grade 3+): Infection · patients with primary CNS lymphoma
Cytarabine plus high‐dose methotrexate probably leads to higher infections (grade 3 to 4) compared with high‐dose methotrexate alone (moderate certainty).
1 finding from 1 review
Intervention not reported
Infection‐ related mortality
The intervention showed no clear difference in infection‐ related mortality (low certainty).
1 finding from 1 review
Intervention not reported
Infection‐ related mortality
The intervention showed no clear difference in infection‐ related mortality (low certainty).
1 finding from 1 review
Time to resolution · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
Serious adverse events within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
All‐cause mortality up to day 28 · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
Admission to hospital or death within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
Resolution of symptoms · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found